Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
Haraoui
Boulos
B
D000906:Antibodies; D018501:Antirheumatic Agents / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000906:Antibodies; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha